Morningstar

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

Provided by GlobeNewswire

SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that Myriad management will participate in three upcoming healthcare conferences.

  • The UBS Global Healthcare Conference with a fireside chat on Tuesday, Nov. 10, 2026, at 1:15 pm ET.

  • The 2026 Stephens Investment Conference with a fireside chat on Wednesday, Nov. 18, 2026, at 3:00 pm ET.

  • The 38th Annual Piper Sandler Healthcare Conference with a fireside chat on Wednesday, Dec. 2, 2026, at 12:30 pm ET.

The presentations will be available through live audio webcast links in the investor information section of Myriad’s website at investor.myriad.com. 

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com.

Investor Contact 
Matt Scalo 
(801) 584-3532 
IR@myriad.com 

Media Contact 
Andria Rosell
(385) 202-3510
PR@myriad.com


The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

4 Growth Stocks to Buy While They’re Still Undervalued

Plus, the outlook for the AI trade after last week’s selloff.
David Sekera, CFA and Sarah Hansen

3 of the Best Core Stocks to Own

These core stocks with wide economic moats are good long-term investments if you can buy them at a discount.
Susan Dziubinski

The 10 Best Companies to Invest in Now

The stocks of these high-quality companies look cheap today.
Tori Brovet

Your Year-End Financial Checklist: 5 Things to Tackle Before 2027

Christine Benz explains how to approach portfolio rebalancing, charitable giving, and retirement contributions.
Christine Benz and Valentina Djeljosevic

Why Morningstar Thinks Anthropic Is Worth $1.7 Trillion

A look at how we arrive at our base-case valuation for the AI lab, along with bull and bear scenarios.
Malik Ahmed Khan, CFA

Sponsor Center

Site Index
United States Flag United States

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.